The Exchange Nordic Growth Market NGM AB, which is owned by Börse Stuttgart, is a Swedish stock exchange with authorization from the Swedish Financial Supervisory Authority to operate a regulated market, Main Regulated, a multilateral trading platform, Nordic MTF, and an SME Growth Market, Nordic SME. On the regulated market Main Regulated, listing and trading of shares and equity-related ... Friskrivning från ansvar Integritetspolicy Stureplan 2, 114 35 Stockholm | contact@ngm.se | 08 566 390 00 Exchange trading hours Exchange trading hours and Holidays Below is a presentation of NGM’s market segments and the times that normally apply for each respective market segment.

Understanding the Context

All times are stated in Central European Time (CET). Normal Trading Day 1 N.B. The same definitions shall apply to these Market Maker Rules as those set out in the Rules for members of Nordic Growth Market NGM AB applicable from time to time. In accordance with section 3.10 in Rules for members of Nordic Growth Market NGM AB, a Market Maker shall apply the requirements on volume, spread and presence set out in the Exchange’s Market Maker Rules applicable from ...

Key Insights

The exchange Price list. Current Price Lists Tech and Market Data Elasticia Service Providers Elasticia Connectivity and Technical Services Market Data - Vendors and Corporate clients Listing Bonds Exchange trades products Main Regulated Nordic AIF Nordic Pre Market Nordic SME - NGM PepMarket Primary Market Products NDX and MTF Trading Trading fees Trading fees (equity) Market Maker Exchange ... Seeking Alpha: NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR ... SOUTH SAN FRANCISCO, Calif., (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM), a biotechnology company focused on discovering and developing transformative therapeutics for ...

Final Thoughts

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR ...